CompletedPHASE1, PHASE2NCT00489840
Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate
Studying Central serous chorioretinopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Manhattan Eye, Ear & Throat Hospital
- Principal Investigator
- Lawrence A. Yannuzzi, MDManhattan Eye, Ear & Throat Hospital
- Intervention
- Anecortave Acetate Sterile suspension 15 mg(drug)
- Enrollment
- 5 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2007
Study locations (2)
- Manhattan Eye, ear & Throat Institute, New York, New York, United States
- Vitreous-Retina-Macula Consultants of New York,PC, New York, New York, United States
Collaborators
LuEsther T. Mertz Retinal Research Center · Alcon Research
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00489840 on ClinicalTrials.govOther trials for Central serous chorioretinopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06527326the Study of the Association Between the Gut Microbiota and Central Serous ChorioretinopathySecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGNCT06346405Central Serous Chorioretinopathy and Micropulse Laser TreatmentFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGNANCT05570591Subthreshold Nanosecond Laser for Non-resolving Central Serous ChorioretinopathyNova Eye Medical Pty Ltd.
- RECRUITINGNCT05589974Choroidal Blood Flow in Acute and Chronic Central Serous ChorioretinopathyHelse Stavanger HF